VLIYaNIE TsINAKALTsETA (MIMPARY) NA POChEChNUYu OSTEODISTROFIYu U PATsIENTOV, NAKhODYaShchIKhSYa NA PROGRAMMNOM GEMODIALIZE
https://doi.org/10.14341/osteo2014125-29
Abstract
В статье представлен обзор современной литературы и результаты наших исследований, обобщающие экспериментальные и клинические данные о влиянии цинакалцета на гормонально-биохимические показатели фосфорно-кальциевого обмена, на маркеры костного метаболизма, минеральную плотность костей, также на гистоморфометрические показатели почечной остеодистрофии у гемодиализных пациентов с вторичным гиперпаратиреозом
References
1. Martinez I., Saracho R., Montenegro J., Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis (1997) 29: 496-502.
2. Rodriguez M., Nemeth E., Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol (2005) 288: F253-F264.
3. Slatopolsky E., Finch J., Clay P., Martin D., Sicard G., Singer G., Gao P. - A novel mechanism for skeletal resistance in uremia. Kid Int 58: 753-61, 2000.
4. Almaden Y., Hernandez A., Torregrosa V. et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998; 9: 1845-1852.
5. Schoppet M., Shanahan C.M. Role for alkaline phosphatase as an inducer of vascular calcification in renal failure? Kidney Int 2008; 73: 989-991.
6. Nemeth E.F., Heaton W.H., et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004; 308(2): 627-35.
7. Brown E.M., Gamba G., Riccardi D. et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature1993; 366: 575-580.
8. Garrett J.E., Capuano I.V., Hammerland L.G., Hung B.C., Brown E.M., Hebert S.C., et al. Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 1995; 270(21): 12919-25.
9. Doherty T.M., Fitzpatrick L.A., Inoue F., et al. Molecular, endocrine, and genetic mechanisms of arterial calcification. Endoc Rev 2004; 25: 629-72.
10. Ferreria M.A. Diagnosis of renal osteodystrophy, when and how to use biochemical markers and non-invasive methods, when bone biopsy is needed. Nephrol Dial Transp. 2000; 15(suppl 5): 8-14.
11. Hodsman A.B. // Perit. Dial. Intern. 2001. - Vol. 21, suppl. 3. - S. 247-255.
12. Рожинская Л.Я., Егшатян Л.В. Патология костной системы при вторичном гиперпаратиреозе у пациентов с терминальной стадией хронической болезни почек на заместительной почечной терапии (гемодиализ). Журнал «Остеопороз и остеопатии». № 1. 2010г. с. 21-25.
13. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease / Am. J. Kidney Dis. 2003. Vol. 42. P. 1-201.
14. Coen G., Ballanti P., Bonucci E., et al. Bone markers in the diagnosis of low turnover osteodystrophy in hemodialysis patients. Nephrol Dial Transpl 1998; 13: 2294-2302.
15. Spasovski G., et al. Poster at ISN Nexus, Copenhagen, Denmark; September 20-23. 2012.
16. Regidor D.L., Kovesdy C.P., Mehrotra R., et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203.
17. Shantouf R., Kovesdy C.P., et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1106-14.
18. Park J.C., Kovesdy C.P., Duong U. et al. Association of serum alkaline phosphatase and bone mineral density in maintenance hemodialysis patients. Hemodial Int 2010; 14: 182-192.
19. Iimori S., Mori Y., Akita W., et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients - a single-center cohort study. Nephrol Dial Transplant. 2012; 27: 345-351.
20. Miller P.D. // Curr. Osteoporos. Rep. - 2005. - Vol. 3 (1). - P. 5-12.
21. Kalantar-Zadeh K., Kuwae N., Regidor D.L. et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780.
22. Gupta R.K., Voss D.M., McHutchison A.G., Hatfield P.J. Osteitis fibrosa cystica (brown tumor) in a patient with renal transplantation: Report of a case with aspiration cytodiagnosis // Acta Cytol. 1992. Vol. 36. P. 555-558.
23. Christiansen P., Steiniche T., Brixen K. Et al. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients. J. Bone, 1997, № 21, Р. 93-97.
24. Stehman-Breen C., Sherrard D., Alem A. et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 2200-2205.
25. Urena P., Bernard-Poenaru O., Ostertag A., et al. Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrology Dialysis Transplantation, Volume18, Issue11, p. 2325-2331. 2003.
26. Егшатян Л.В., Рожинская Л.Я., Кузнецов Н.С. и др. Лабораторно - инструментальные характеристики почечной остеодистрофии при тяжелом течении вторичного гиперпаратиреоза у гемодиализных пациентов. Материалы V российского конгресса по остеопорозу и другим метаболическим заболеваниям скелета, Москва 18-20 ноября 2013, стр 121.
27. Егшатян Л.В. Эффективность терапевтического и хирургического лечения вторичного гиперпаратиреоза у пациентов, получающих заместительную почечную терапию программным гемодиализом. Дисс.. к.м.н., ФГБУ ЭНЦ, Москва 2012 г.
28. Cunningham J. What is the optimal regimen for vitamin D? Kidney Int 1999; 56(suppl 73): S-59-S-64.
29. Block G.A., Port F.K. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis (2000) 35: 1226-1237.
30. Costa A.F., Dos Reis L.M., Ribeiro M.C., et al.: Effects of calcitriol on parathyroid function and on bone remodelling in secondary hyperparathyroidism. Nephrol Dial Transplant 18: 743-749, 2003.
31. Gallieini M., Brancaccio D., Padoverse P., et al.: Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. Kidney Int 42: 1191-1198, 1992.
32. Martin K.J., Gonzalez E.A. et al.: Paricalcitol safely and effectively reduces the levels of intact parathyroidhormonein patients on hemodialysis. J AmSoc Nephrol 9: 1427-1432, 1998.
33. Andress D.L., Norris K.C., Coburn J.W., et al.: Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-279, 1989.
34. Young E.W., Akiba T., Albert J.M., et al.: Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am JKidney Dis 44: 34-38, 2004.
35. Walling M.W.: Intestinal Ca and phosphate transport: Differential responses to vitamin D3 metabolites. Am J Physiol 233: E488-494, 1977.
36. Block G.A., Martin K.J., De Francisco A.L., et al.: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004.
37. Lindberg J.S., Culleton B., Wong G., et al.: Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicenter study. J Am Soc Nephrol 16: 800-807, 2005.
38. Lindberg J.S., Moe S.M., Goodman W.G., et al.: The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 63: 248-254, 2003.
39. Quarles L.D., Sherrard D.J., Adler S., et al.: The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of endstage renal disease. J Am Soc Nephrol 14: 575-583, 2003.
40. Егшатян Л.В., Рожинская Л.Я., Кузнецов Н.С., и др. Цинакалцет при вторичном гиперпаратиреозе у пациентов, находящихся на гемодиализе. «ВРАЧ», № 6. 2011, с. 66-71.
41. Urena P., Jacobson S.H., Zitt E., Vervloet M., et al.: Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice - the ECHO observational study. Nephrol Dial Transplant 2009; 24: 2852-2859.
42. Bover J., R. Perez, M. Molina, et al. Cinacalcet Treatment for Secondary Hyperparathyroidism in Dialysis Patients: An Observational Study in Routine Clinical Practice. Nephron Clin Pract 2011; 118: c109-c121.
43. Cunningham J., Danese M., Olson K. et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism // Kidney Int. 2005. V. 68. P. 1793-1800.
44. Fujii N., Hamano T., Taniguchi M., et al. Cinacalcet reduses the incidence of hip fracture in haemodialysis patients with Hyperparathyroidism, hyperphosphatemia or low BMI. presented at ERA-EDTA 2011, Prague, Czech Republic. Abstract Su 2011.
45. Yeong-Hau H. Lien, Arnold L. Silva and David Whittman. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant (2005).
46. Belozeroff V., Goodman W.G., Ren L. et al. Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 673-679.
47. Malluche H.H., Monier-Faugere M.C., Wang G., et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol (2008) 69: 269-278.
48. Block G.A., Martin K.J., DE Francisco A.L., et al.: Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350: 1516-1525, 2004.
49. Tsuruta Y., Okano K., Kikuchi K., et al. Effects of cinacalcet on bone mineral density and bone markers in hemodialysis patients with secondary hyperparathyroidism. Clin Exp Nephrol. 2013 Feb; 17(1): 120-6.
50. Егшатян Л.В., Рожинская Л.Я., Кузнецов Н.С., и др. Влияние агониста кальций-чувствительного рецептора (Цинакальцета) на метаболизм и минеральную плотность костей у гемодиализных пациентов в сравнении с результатами паратиреоидэктомии при тяжелом течении вторичного гиперпаратиреоза. Материалы V российского конгресса по остеопорозу и другим метаболическим заболеваниям скелета, Москва 18-20 ноября 2013, стр 122.
51. Behets G. et al. Poster at ISN Nexus, Copenhagen, Denmark; September 20-23, 2012.
52. Koizumi M., Komaba H., Nakanishi S., et al. “Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism,” Nephrol Dial Transpl, v. 27, n. 2, p. 784-790, 2012.
53. Hryszko T., Brzosko S., Rydzewska-Rosolowska A., et al. Cinacalcet lowers FGF-23 level together with bone metabolism in hemodialyzed patients with secondary hyperparathyroidism. Int Urol Nephrol. 2012 Oct; 44(5): 1479-86.
Review
For citations:
ROZhINSKAYa L.Ya., EGShATYaN L.V. VLIYaNIE TsINAKALTsETA (MIMPARY) NA POChEChNUYu OSTEODISTROFIYu U PATsIENTOV, NAKhODYaShchIKhSYa NA PROGRAMMNOM GEMODIALIZE. Osteoporosis and Bone Diseases. 2014;17(1):25-29. (In Russ.) https://doi.org/10.14341/osteo2014125-29
Views:
588
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
